AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$TARS

Lin Elizabeth Yeu sold $278K of TARS (indirect holdings)

Lin Elizabeth Yeu (Chief Medical Officer) sold 3,180 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $87.50 ($85.00–$90.00, $0.28M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lin Elizabeth Yeu
Published Sep 9, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TARS
Bearish
medium confidence
Mentioned
$TARS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSBearishLow
01

Why it matters

Insider sale of $278K may slightly affect investor perception but limited market impact

02

Market read

Small insider sale; limited trading relevance

03

What to watch

No disclosed reason; could be tax planning or diversification

Relevance 3/10Novelty 4/10Timing: filed Sep 9 2026

Background

Form 4 filing discloses insider transaction for Tarsus Pharmaceuticals

Company-level read

Ticker impact

$TARSBearishMedium confidence
Context

Chief Medical Officer sold 3,180 shares for $278K via 10b5-1 plan

Expected impact

Potential modest downside pressure in near term

Evidence & confidence

Sale size is modest relative to market cap, but CMO insider selling via pre-arranged plan may influence sentiment

Market effects

Sector

Minimal impact on biotech sector

Regional

None

Global

Low

Counterpoint

What could challenge this read

Sale may be routine under 10b5-1, not indicative of future performance

Key entities

  • Officer
    Lin Elizabeth Yeu

    Chief Medical Officer of Tarsus Pharmaceuticals

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TARS insider trading history →

Related articles

SEP 16
$TARSMed

TARS Reinstated by Barclays -- Rating Upgraded to Overweight

Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.

gurufocus.com2 min
SEP 10
$TARSHighAI 8/10

Tarsus Pharmaceuticals, Inc. (TARS): Completion of Acquisition or Disposition of Assets

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote

SEC EDGAR 8-K2 min
SEP 8
$TARSMed

Jefferies raises Tarsus Pharmaceuticals price target on guidance

Jefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.

investing.com2 min
SEP 4
$TARSMed

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a Phase 3 investigational therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is expected to report topline data in 2029. The acquisition expands Tarsus' pipeline and supports its eye care strategy. TARS shares closed at $83.21 on Thursday, up 0.54%.

rttnews.com2 min
SEP 4
$TARSMed

A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one.

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a late-stage oral therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is in a Phase 3 trial with topline data expected in 2029. Tarsus believes ALK-001 could be a blockbuster treatment for this inherited retinal disease with no FDA-approved therapies.

stocktitan.net2 min